Last Updated : April 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Keytruda | Pembrolizumab | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Lynparza | Olaparib | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Firazyr | icatibant | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Zevalin | Ibritumomab tiuxetan | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Alecensaro | alectinib | ALK-positive NSCLC | Pending | |||
| Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Pending | |||
| TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Pending | |||
| TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
| TBC | fruquintinib | Metastatic colorectal cancer (mCRC) | Pending | |||
| Xeljanz | tofacitinib | Cancelled |
Last Updated : April 16, 2024